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Abstract
The Monitoring Studies (MS) program, the approach developed by RedETS to generate
postlaunch real-world evidence (RWE), is intended to complement and enhance the
conventional health technology assessment process to support health policy decision
making in Spain, besides informing other interested stakeholders, including clinicians
and patients. The MS program is focused on specific uncertainties about the real effect,
safety, costs, and routine use of new and insufficiently assessed relevant medical devices
carefully selected to ensure the value of the additional research needed, by means of
structured, controlled, participative, and transparent procedures. However, despite a
clear political commitment and economic support from national and regional health
authorities, several difficulties were identified along the development and implementation
of the first wave of MS, delaying its execution and final reporting. Resolution of these
difficulties at the regional and national levels and a greater collaborative impulse in the
European Union, given the availability of an appropriate methodological framework already
provided by EUnetHTA, might provide a faster and more efficient comparative RWE of
improved quality and reliability at the national and international levels.
Background
Governments are committed to controlling increasing healthcare expenditure, contributing to
the efficiency and sustainability of healthcare systems, within a context of dwindling budgets,
exacerbated by the double impact of the past economic and financial crisis beginning in 2008
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and the current direct and collateral pandemic effects provoked by
COVID-19. As a result, demand for evidence and justification of
value, in the context of innovation and health technology assess-
ment (HTA), are increasingly required, either to ensure efficacy
and safety or, in addition, to support funding, coverage and reim-
bursement decisions, or price negotiations (1). Although this
decisional process differs among countries and even regions
within countries with decentralized health systems such as
Spain, Canada, or Italy, most of them use HTA, supported by
clinical trial-based systematic reviews, as the main informational
source (2;3). Additional information on health outcomes and
costs under context-specific or “real-world” conditions, including
outcomes data relevant for patients, is increasing but still scarce (3).
Evidence standards for HTA are threatened by incomplete and
possibly misleading evidence, which is particularly present in pro-
cedures and medical devices where the evidence is usually much
less extensive and robust than the evidence for drugs, given the
less stringent existing regulatory requirements (4). Other domains
relevant for medical device assessment, such as learning curves for
capacity building, organizational issues, or environmental impact,
are also commonly ignored. This situation calls for additional
informational sources such as postlaunch evidence-generation
(PLEG) studies, which can provide postmarketing real-world evi-
dence (RWE), enlarging the scope of HTA in the lifecycle of tech-
nologies according to the new HTA definition (5–7).
The PLEG studies can be boosted by different requests and
purposes. Some of them can cover academic or technology devel-
opers’ objectives. Others, however, come from a request of health
authorities because of their need to rely on additional evidence to
make decisions.
The healthcare system in Spain is decentralized, with a com-
mon benefit package defined at the central level with the agree-
ment of Regional Health Authorities under the Interterritorial
Council of the National Health System. The provision and financ-
ing of health care rely on the Regional Health Authorities. The
Directorate General of the common portfolio of services of the
National Health System (NHS) and Pharmacy (DGPSPh) of the
Spanish Ministry of Health (MoH) is the national organization
responsible for coverage approval of all health technologies in
Spain. The Spanish Network for Health Technology Assessment
and Services of the NHS (RedETS) is the organization responsible
for appraising available evidence about the safety, effectiveness,
cost-effectiveness, organizational aspects, and the legal, ethical,
organizational, and environmental issues of all nonpharmaceuti-
cal technologies. Detailed information about the functions, com-
position, and activity of RedETS has been recently published by
this journal (8). The Spanish Agency of Medicines and Medical
Devices (AEMPS) is a state agency linked to the MoH, responsible
for assessing the quality, safety, and efficacy of medicines before
market access of pharmacological technologies.
From 2015, the MoH launched the controlled use studies
(from the Spanish: estudios de uso tutelado), a type of observa-
tional study to inform policy decision making on public funding
of relevant health technologies before their inclusion in the
Benefit Portfolio of the Spanish NHS (BP) (9). Later in 2015,
the MoH started requesting RedETS for PLEG studies on medical
devices to inform coverage decisions in the context of the NHS.
These studies were officially regulated in an MoH order SSI/
1356/2015 (10), which establishes the aims and main characteris-
tics of the so-called “Estudios de Monitorización” in Spanish (i.e.,
Monitoring Studies [MS]). MS are prospective observational and
single-arm studies of selected technologies at different stages of
their postlaunch phase when evidence is limited. MS are aimed
at technologies already included in the BP to assess specific con-
ditions of use or effects in certain target population groups (11–
13). MS’ general purpose is reducing uncertainty while providing
RWE mainly on the safety and effectiveness of the application of
highly relevant technologies in the Spanish NHS under real prac-
tice circumstances. Economic and organizational impact exami-
nation are also included in MS. At present, MS are intended to
support decision making on public funding of nonpharmaceutical
technologies.
The coordination of MS is shared by the DGPSPh and
RedETS. Although the DGPSPh develops all political, economic,
administrative, organizational, and logistic tasks, the technical
coordination and scientific exploitation are independently carried
out by the designated RedETS’ agency, including the MS protocol
development, the study design, data analyses, and final reporting.
MS favor early technology accessibility to clinicians and patients,
subject to RWE generation.
The aim of this publication is to describe the planned steps
and procedures supporting MS in the context of RedETS, together
with a summary of the operational experiences and some lessons
learnt from the first wave of MS.
Topic Identification for MS
The DGPSPh of the MoH is responsible for the selection of topics
for PLEG at the proposal of the National Commission of
Provision, Insurance and Financing (CPAF) of the MoH, accord-
ing to the Law SSI/1356/2015 (10) and the Royal Decree 1030/
2006 (11). MS usually originate when specific relevant informa-
tional/research needs hindering decision making arise in relation
to previous RedETS reports (14–16). The CPAF proposal must be
accompanied by a clear indication of the fulfillment of the criteria
to select and prioritize health technologies requiring additional evi-
dence-generation indication, according to the specific EUnetHTA
recommendations delivered by 2012 (17). The proposals are care-
fully considered given the scientific and technical complexity,
time constraints and costs of the procedure, as well as the necessary
strategic involvement of several healthcare centers across different
Spanish autonomous regions, scientific societies, related industries,
and patient associations. Each MS is assigned to a RedETS’ agency
that will be responsible for conducting the technical and scientific
part of the PLEG study.
Design, Protocol Structure, and Contents of MS
An MS is the specific PLEG study format devoted to gather RWE
in the Spanish NHS context in the field of medical devices. It cor-
responds to observational single-arm studies that prospectively col-
lect evidence about the real performance of medical devices in the
Spanish NHS. All MS are applied under an investigational protocol,
limiting the provision of the assessed technology and guiding its
indication to a previously selected set of referral centers.
The MS protocols are the core documents describing the
design, objectives, methodology, and overall organization of the
study, guiding all activities of participant research groups. Each
MS protocol is prepared by the designated agency and consists
of two sections (9). The first section includes: (i) a health technol-
ogy description covering the application procedures and organiza-
tional arrangements needed, together with the diffusion degree of
the studied health technology in Spain and other EU countries, as
well as comparative information with competing available
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alternatives. (ii) A synopsis on the target health condition and its
current standards of care; the main targeted population and
potential subgroups of interest; relevant contextual organizational
issues related to health technology acquisition, commissioning,
and operation; as well as costing, social, and ethical issues related
to the technology. This part will end with the main arguments
justifying the development of the MS (17), including the knowl-
edge gaps and research needs to address, as well as potential
worldwide-related studies currently underway. (iii) The objectives
of MS. (iv) Indications of use of the technology. (v) A subsection
with the conditions of use of the technology under evaluation to
allow appropriate selection of participant referral centers, includ-
ing all material, human, legal, and educational/training require-
ments for appropriate technology application.
The second section covers the methodological and implemen-
tation issues of MS, including: (i) patient eligibility criteria. (ii)
Minimum data set requirements, including sociodemographic
and clinical information, use of healthcare resources and health
outcomes accounting for favorable and unfavorable effects, with
special interest for relevant predefined subgroups of patients
(see Table 1 with outcome measures currently used in ongoing
MS). (iii) The need for short, medium, or long-term follow-up.
(iv) Sample-size estimations and expected MS duration. MS dura-
tion will vary according to sample-size requirements, condition
prevalence, the number of participant referral centers, character-
istics of the assessed outcomes, and estimated follow-up visits.
(v) A specific informed consent form is applied and signed by
all participants.
Data gathering is supported by an electronic information sys-
tem (SIEM) embedded into a web platform developed and man-
aged by the DGPSPh (18). The SIEM hosts a data collection form
for the initial stage, the intervention phase, and the monitoring
period. Patient identification data are coded and accessible only
to participant centers (referral centers), ensuring patient anonym-
ity. Several types of automated warnings help identify relevant
health events related to safety, as well as missing or improperly
entered data.
Protocol development is open to participation of experts nom-
inated by regional health authorities in the Spanish NHS and
related scientific societies. Additionally, the study protocol is
revised by interested patient organizations and industry represen-
tatives. All experts, patients, and professionals participating in any
type of MS activity complete an individual conflict of interest dec-
laration. Finally, the reviewed protocol is submitted for approval
by the CPAF.
Due to the absence of validated quality standards to assess reg-
istries providing RWE for HTA purposes at the time of launching
the first MS, RedETS relied on the general guidelines for compa-
rable development of patient registries, proposed by the
EU-funded Joint Action “Cross Border Patient Registries
Initiative” (PARENT) (19). RedETS soon aligned its MS criteria
of quality checking to those suggested by EUnetHTA JA3 in the
REQueST framework (20).
Selection of Referral Healthcare Centers
The selection of eligible healthcare centers, commonly tertiary
hospitals across all Spanish autonomous communities, begins
after the approval of the protocol by the CPAF (10). This is a
decentralized selection process happening at the regional level
under the control of every local health authority. Selected hospi-
tals are checked and confirmed by the MoH according to the
information provided by an eligibility self-assessment question-
naire, developed between RedETS and the DGPSPh. A large num-
ber of referral centers will be required when monitoring a highly
needed technology, when a wider sample size is required and
when assessing technologies devoted to low-prevalence clinical
conditions.
Operational Procedures and Intended Use of Results
Every RedETS agency in charge of an MS has the following tasks
related to its execution (10): (i) receiving and analyzing data from
all participating centers. (ii) Monthly checking on SIEMs’ data
completeness and quality. (iii) Immediate communication to
DGPSPh of all potentially technology related adverse events to
consider possible changes in MS protocol or even MS discontin-
uation. (iv) Ensuring that data collection and transmission com-
ply with legal requirements on protection of personal data. (v)
Reviewing the informed consent forms to verify the information
provided to patients. (vi) Annual deliverance of a technical report
for the CPAF, updating the information on the MS evolution.
Early communication of relevant recruitment delays threatening
the desired sample size is highlighted, together with a realistic
suggestion of expanded period when needed.
Within 3 months after completing the SIEMs’ data registra-
tion, the corresponding agency prepares the preliminary final
technical report by processing, analyzing, and interpreting all
SIEM-contained information for external expert and industry
review. The final report is submitted to DGPSPh and used for
decision making by the CPAF regarding the status of the technol-
ogy evaluated in the common benefit package, according to the
report’s conclusions and other factors such as the availability of
therapeutic alternatives and its estimated organizational and eco-
nomic impact. Decisions could be aimed at keeping the technol-
ogy in the benefit package under the previous conditions of use,
modifying these conditions of use, or even excluding the technol-
ogy from public funding. Whatever the decision, its implementa-
tion requires the publication of a ministerial order, according to
the Royal Decree 1030/2006. Complementary actions could also
be proposed, such as keeping the technology use in selected cen-
ters or making recommendations regarding the reorganization of
resources.
Once completed and approved by the CPAF, all final reports
will be hosted on the RedETS Web site and shared with interested
scientific and patient organizations, as well as with related indus-
try. Subsequently, those providing scientifically relevant results
will be disclosed in appropriate scientific meetings and interna-
tional journals.
The Role of the Industry
Industry representatives have early access to both the preliminary
MS protocol and the preliminary final report, to provide docu-
mented feedback. The DGPSPh of the MoH, together with
authorities of the participant autonomous communities involved
in MS, negotiates the supply and maximum price conditions of
the devices under assessment with the commercializing compa-
nies, requesting them to provide a quarterly communication of
the number of devices/equipment supplied to each participant
center. This periodic information is sequentially used to check
the progression of included cases in each participant center in
SIEM. Companies are also committed to providing all new rele-
vant information published on the monitored health technology.
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The RedETS MS program considers the possibility of using shared
financing mechanisms with the industry (10).
First RedETS Experiences on Health Technologies
under MS
The first MS of RedETS have been funded collaboratively between
the MoH and the regional health authorities. Although regional
health authorities support participant hospitals by reimbursing
all involved direct costs, including the technology under assess-
ment and data gathering, the MoH funds the RedETS participa-
tion to guarantee monitoring and quality assurance processes,
as well as data analyses and report delivery.
Table 1 shows the main general characteristics of all MS cur-
rently monitored by RedETS. In July 2015, the MoH commis-
sioned the first four MS (14–16). Later, two other MS were
approved and commissioned; all of them related to previous
HTA reports (21;22).


















air leak after surgery,
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underlying lung diseases
SESCS • Effectiveness of leak resolution
• Times from implantation to resolution,
drain removal, and hospital discharge











AETS-ISCIII • Effectiveness of dysphagia control
• Reduction in the number of esophageal
dilatations














Osteba • Severity reduction of valve insufficiency
to grade≤ 2 at discharge and 30 days.
• Readmission rates for heart failure and
changes in functional capacity at 30
days.
• Changes in outcomes according to
volume and learning curve
• Safety: major adverse cardiovascular










factors for stroke, with
contraindication to oral
anticoagulation therapy
AETS-ISCIII • Effectiveness of the reduction of
cardiovascular events and mortality
• Changes in outcomes according to
volume and learning curve
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SESCS • Effectiveness of glycemic control
(HbA1c)
• Reduction of events and time in
biochemical hypoglycemia
• Safety: complication rates
• Resource use
• Patients’ experiences






Avalia-t • Effectiveness: Overall survival; Survival
free from adverse events
(cardiovascular events or stroke);
Survival free from LVAD replacement or
explant and Quality of life; Patients´
subgroup with best clinical outcomes
from DAVI; Changes in outcomes
according to volume and learning curve
• Safety: In-hospital death; Cardiac
adverse events (i.e., right heart
failure…); Neurological adverse events
(i.e., stroke…); LVAD device-related
adverse events
• Resource use and organizational
impact: Length of stay in hospital/ICU;








SESCS, Servicio de Evaluación del Servicio Canario de la Salud; AETS-ISCIII, Agencia de Evaluación de Tecnologías Sanitarias del Instituto de Salud Carlos III; Osteba, Servicio de Evaluación
de Tecnologías Sanitarias. Departamento de Salud del País Vasco; Avalia-t, Unidade de Asesoramento Científico-técnico, avalia-t. Axencia de Coñecemento en Saúde (ACIS).
4 Pedro Serrano‐Aguilar et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462321000295
Downloaded from https://www.cambridge.org/core. Complejo Hospitalario Universitario de Vigo, on 05 May 2021 at 06:58:31, subject to the Cambridge Core terms of use, available at
Lessons Learnt and Implications at the National and
European Levels
This article is the first of its kind to describe the real-world expe-
riences of PLEG for medical devices, supported by national and
regional health authorities in the context of the Spanish NHS.
Its specific characteristics, including an officially established
national procedure, supported and funded by the MoH in coop-
eration with regional health authorities, explain the potential
interest of this MS procedure. Although the final reports of first-
generation MS are currently being delivered, awaiting an impact
assessment, this paper includes an analysis of difficulties to over-
come to improve the selection, design, implementation, and
timely execution of future MS.
As commonly happens with medical devices, all technologies
under the MS program reached the market with specific and rel-
evant scientific gaps hampering informed decisions on public
coverage and reimbursement by Spanish health authorities.
Even though medical devices are launched into the market with
more scientific uncertainties than medicines, the use of PLEG
for decision making has been more frequently explored for med-
icines than for other technologies. This situation is influenced by
the unbalanced requirements that regulators make when uncer-
tainties at approval are important enough to potentially have an
impact on the product information and clinical use (23).
Medical devices may be particularly affected by current efforts
to promote early assessment of new short lifecycle technologies,
thereby threatening fair decision making given the common scar-
city, incompleteness, and quality limitations of available evidence.
Despite the value attributed to RWE to inform national deci-
sion making in the Spanish NHS, the commitment and participa-
tion of the MoH and all regional health authorities, and the
adherence of the MS to the essential quality standards for regis-
tries recently agreed by EUnetHTA (20), several relevant prob-
lems were identified by the DGPSPh, in a recent overall review
of the MS processes. Although the first wave of MS required an
average of 18 months from political approval to start, plus three
additional years to deliver the final report, second wave MS signif-
icantly reduced, almost by half, the starting time. The main rea-
sons explaining delays to start selected MS have to do with the
process of political approval of MS proposals and their protocols,
as well as with the later adaptation of the SIEM and the selection
of participant referral hospitals. Besides problems in recruiting
participant referral hospitals, their limited availability of research
infrastructure and professional involvement also contributed to
delays in the recruitment of patients, in reaching the required
sample size and in the adequate and timely data collection.
From this recent overall review process promoted by the MoH
to improve the next generation of MS, the following needs of
actions were identified: (i) to improve the selection and prioritiza-
tion of technologies to include in MS; (ii) to anticipate earlier
identification and inclusion of new devices similar to those
under MS; (iii) to streamline all administrative tasks—shortening
times, avoiding unnecessary paperwork, and setting a maximum
target time of 7 months from approval to beginning of MS; (iv)
to reinforce the role of regional authorities in selecting referral
centers with existing research infrastructure; (v) to boost earlier
and more intense collaboration among RedETS, clinical experts,
patients, and industry representatives in protocol development
and SIEM adaptation; and (vi) to provide incentives and intensify
communication and feedback with all involved professionals to
improve patient recruitment and quality and timely data
collection to allow appropriate analysis and earlier delivery of
the final report. Figure 1 illustrates the main problems detected,
the possible solutions, and the corresponding organizations
responsible for implementation.
The systematic data collection (24) of patients’ features, relevant
health outcomes, and resource use, under real-world scenarios sub-
ject to quality control monitoring, reduces uncertainty in national
and regional coverage decision making in context-specific settings
(25;26). After technology inclusion, additional evidence regarding
diffusion and patterns of clinical use in real practice could also
be potentially monitored, providing valuable information on
longer-term outcomes either to confirm or reverse previous deci-
sions or to help define its appropriate implementation and use
from an organizational and clinical perspective, respectively. The
production of RWE, specifically for devices and surgical interven-
tions, should consider the potentially modifying effect of the vol-
ume and the learning curve of the operator.
Grilli and Taroni (26) reported that some observational studies
on emergent technologies showed that evidence collected on rou-
tine use did not always support earlier trial published outcomes,
providing lower outcome values than those coming from experi-
mental studies. Real-world settings and patients might differ
from experimental studies, according to age and comorbidity dis-
tribution. Additionally, local patterns of clinical practice might
diverge from experimental protocols by merging other interven-
tions (26). Regardless of the hierarchy of evidence of observa-
tional MS, these are intended to supplement the insufficient
evidence provided from available clinical trials, either when the
evidence base to support decisions is immature or when there is
substantial uncertainty surrounding the effectiveness, safety, or
cost-effectiveness, by measuring relevant outcomes for patients
under real-world conditions (27). In addition, information
about uncertainties stemming from surrogate end points, long-
term efficacy, effects in specific subgroups, a product’s use in clin-
ical practice (e.g., its place in the treatment algorithm; treatment
duration and adherence), or changes in standard of care, could
be also provided (23).
According to Grilli and Taroni (26), “the longer it takes for
coverage decisions, the greater, broader and more organized is
the pressure on policy-makers.” In fact, the time required to com-
plete the first four MS by RedETS has been longer than expected
due to initial difficulties in setting the SIEMs, recruiting partici-
pant centers and patients, and in completing all required entry
and sequential data. Meanwhile, concomitant industry marketing
strategies activating patient and mass media expectations were
observed, putting pressure on clinicians and health policy deci-
sion makers (21).
In spite of the progress made in EUnetHTA Joint Action III to
perform collaborative assessments on relative effectiveness (REA)
and joint early dialogues with the industry, many limited experi-
ences have been reported on the development of collaborative
PLEG studies to complement systematic reviews with context-
specific RWE for the assessment and decision support regarding
medical devices. However, considering that any kind of additional
data collection is resource- and time-consuming, and that the pro-
cess for selecting technologies for further research used to be
informal and heterogeneous among settings, the EUnetHTA
Joint Action 2010–2 (17), and others (27), promptly provided a
set of selection/prioritization criteria to guide selecting technolo-
gies for which complementary studies are of real value. Besides, at
present, the EUnetHTA work package 5B is developing two pilot
PLEG studies on pharmaceuticals and one pilot PLEG study on
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medical devices, specifically on left ventricular assist devices
(DAVI) for destination therapy. Some of the difficulties faced in
the case of the collaborative PLEG studies are related to sharing
health data among different countries. As a result, the DAVI
pilot will be focused on identifying evidence gaps and setting
and gathering information on a minimum data set (28). Solving
data-sharing barriers and expanding experiences of collaborative
registries would be of great interest for future European HTA col-
laborations. Similarly, in addition to the experiences on joint REA
and early dialogues, collaboration in PLEG studies for medical
devices could also contribute to increased EUnetHTA productiv-
ity and impact, reducing the time needed and overall costs to
deliver these types of observational reports across the EU (26).
An EUnetHTA survey examining the extent to which HTA
agencies use sources of RWE such as registries (29) showed that,
particularly in Europe, some agencies use clinical and administra-
tive databases, besides clinical registries to gather additional data for
HTA. Less than half, however, currently employ criteria for quality
checking these data sources, in most cases defined by each organi-
zation rather than external bodies with standardized tools. The
recent development of the REQueST instrument for quality assess-
ment of previously elsewhere developed registries is expected to
ease international cooperation in the development or early adapta-
tion of registries specifically designed for HTA purposes under the
EUnetHTA framework and beyond (20).
Given the increasing growth of international and national
PLEG studies, similar to the RedETS MS program to provide con-
textual data and support local decision making, some concern
emerges regarding the possibility of a progressive effort reduction
by the healthcare industry to generate sufficient and valid scien-
tific evidence for all dimensions required for HTA and approval.
This concern, together with the need to limit the financial effort
required by this type of PLEG studies, should give more promi-
nence to the activities of early scientific advice between HTA
organizations and the industry representatives, to ensure that all
relevant required information to inform decision making is
promptly provided by the industry. The financial contribution
of the industry in this type of study is, consequently justified,
according to the aforementioned considerations (27). Despite
the fact that the RedETS MS program envisaged the potential
funding contribution by the involved industry (10), no experi-
ences of shared financial responsibilities have been currently
developed by the MoH in the specific field of PLEG studies for
medical devices. The main reasons explaining this initial decision
lie in the convenience of developing previous experiences with
simplified implementation models, in which the most relevant
activities in each stage of the MS could be tested, characterized,
and established. In addition, it has been possible to estimate the
costs of MS, before adding administrative and financial complex-
ities by involving the industry.
Finally, consideration is required on how the new Medical
Device Regulation (MDR) at the European Union level will affect
the availability and quality of data at the time of launching new
health technologies. PLEG studies should have been aligned
with this recently adopted MDR, but they were immediately post-
poned until May 2021 due to the current challenges related to the
pandemic crisis (30). The new MDR was developed by focusing
on patient health and safety as core principles, requiring compa-
nies to provide data on safety under real practice conditions. On
such a basis, there will be a need to discuss with regional systems,
professionals, patients, and companies how to adapt PLEG studies
to these new requirements to better address the information needs
to better support decision making on the approval and provision
of new medical devices and in vitro diagnostics.
As a brief conclusion, the RedETS MS program is intended to
complement and enhance the conventional HTA process to sup-
port stakeholder decision making in Spain, including health
authorities, clinicians, and patients. The MS program is focused
Figure 1. Problems encountered and suggested solutions by responsible organiza-
tions. The main problems encountered and the possible actions to minimize their
impact affect most of the main phases of the MS and the stakeholders involved in
the selection, approval, design, and execution of MS, as well as the analysis and
final reporting.
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on specific uncertainties about the real effect, safety, costs, and
routine use of new and insufficiently assessed relevant medical
devices carefully selected to ensure the value of the additional
research needed, by means of controlled, participative, and trans-
parent procedures. However, despite a clear political commitment
and economic support from national and regional health author-
ities, several difficulties were identified during the development
and implementation of the first wave of MS, delaying its execution
and final reporting, challenging their impact on political deci-
sions. Resolution of these difficulties at the national level and a
greater collaborative impulse at the European level, given the
availability of an appropriate methodological framework already
provided by EUnetHTA, might provide a faster and more efficient
comparative RWE of improved quality and reliability.
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